Drug intelligence / Profile preview

ch806

Development stage: Unknown
Lead developer: AbbVie
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Ch806 is a chimeric monoclonal antibody that targets a unique epitope on the Epidermal Growth Factor Receptor (EGFR). It specifically binds to both the de2-7 EGFR variant (EGFRvIII) and overexpressed wild-type EGFR in tumors, but does not bind to normal tissue EGFR expressed at physiological levels. This tumor-specific targeting differentiates it from other anti-EGFR therapies and potentially avoids the normal tissue toxicity seen with other EGFR-targeting antibodies.

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)

Beyond the preview

Go deeper on ch806.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ch806.

Explore the full profile